PDE 4 inhibitors: The use of molecular cloning in the design and development of novel drugs

PDE 4 inhibitors: The use of molecular cloning in the design and development of novel drugs

Bibliographic Details
Main Authors:	Hughes, B, Owens, R, Perry, M, Warrellow, G, Allen, R
Format:	Journal article
Published:	1997

Similar Items

CDP840: a novel inhibitor of PDE-4.
by: Perry, M, et al.
Published: (1998)

Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.
by: Huston, E, et al.
Published: (1997)

SUPPRESSION OF ANTIGEN-INDUCED AIRWAY RESPONSES AND BRONCHIAL HYPERRESPONSIVENESS BY CDP840, A NOVEL STEREOSELECTIVE INHIBITOR OF PHOSPHODIESTERASE TYPE-IV
by: Hughes, B, et al.
Published: (1995)

Insilico discovery of novel Phosphodiesterase 4 (PDE4) inhibitors for the treatment of psoriasis: Insights from computer aided drug design approaches
by: Abdullah R. Alanzi, et al.
Published: (2024-01-01)

Insilico discovery of novel Phosphodiesterase 4 (PDE4) inhibitors for the treatment of psoriasis: Insights from computer aided drug design approaches.
by: Abdullah R Alanzi, et al.
Published: (2024-01-01)

PDE5 inhibitor drugs for use in dementia
by: Atticus H. Hainsworth, et al.
Published: (2023-07-01)

Novel PDE4 inhibitors derived from Chinese medicine forsythia.
by: Tiffany A Coon, et al.
Published: (2014-01-01)

Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
by: Gülru Kayık, et al.
Published: (2017-01-01)

Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities
by: Jinxuan Li, et al.
Published: (2018-05-01)

Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases
by: Vincent Lagente, et al.
Published: (2005-03-01)

Molecular cloning and expression of a human phosphodiesterase 4C.
by: Owens, R, et al.
Published: (1997)

Differential expression and function of PDE8 and PDE4 in effector T cells: Implications for PDE8 as a drug target in inflammation.
by: Amanda G. Vang, et al.
Published: (2016-08-01)

A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition.
by: Didem Demirbas, et al.
Published: (2013-01-01)

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
by: Andrew Blauvelt, et al.
Published: (2023-11-01)

Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease
by: Jingyi Ma, et al.
Published: (2022-09-01)

Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors.
by: Allen, R, et al.
Published: (1999)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
by: Jonathan E. Phillips
Published: (2020-03-01)

The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
by: Hughes, B, et al.
Published: (1996)

Short PDE4 Isoforms as Drug Targets in Disease
by: Elka Kyurkchieva, et al.
Published: (2023-07-01)

Differential Effects of PDE4 Inhibitors on Cortical Neurons and T-Lymphocytes
by: Ryo Hirose, et al.
Published: (2008-01-01)

Design and synthesis of novel indole-quinoxaline hybrids to target phosphodiesterase 4 (PDE4)
by: Bethala Jawahar Luther, et al.
Published: (2019-12-01)

Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimer’s Disease
by: Yan Zhou, et al.
Published: (2021-05-01)

Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors
by: Xu-Nian Wu, et al.
Published: (2018-07-01)

Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems
by: Dakshinamurthy Sivakumar, et al.
Published: (2021-05-01)

Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor
by: Mayasah Al-Nema, et al.
Published: (2020-09-01)

Identification of pyrazolopyridazinones as PDEδ inhibitors
by: Björn Papke, et al.
Published: (2016-04-01)

PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury.
by: Irene Paterniti, et al.
Published: (2011-01-01)

PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?
by: Frank S. Menniti, et al.
Published: (2021-01-01)

New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil
by: Marian Cruz-Burgos, et al.
Published: (2021-02-01)

PDE4 inhibitors: potential protective effects in inflammation and vascular diseases
by: Tianfei Fan, et al.
Published: (2024-06-01)

An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022
by: Letizia Crocetti, et al.
Published: (2022-08-01)

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
by: Dave Singh, et al.
Published: (2020-09-01)

Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
by: Fabrizio Facchinetti, et al.
Published: (2021-11-01)

Genotoxic potential of a novel PDE-4B inhibitor Apremilast by chromosomal aberration and micronucleus assay in mice
by: Muhammad Afzal, et al.
Published: (2020-05-01)

Heterocyclic Nitrogen Compounds as Potential PDE4B Inhibitors in Activated Macrophages
by: Simona Todisco, et al.
Published: (2024-08-01)

Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice
by: Abigail Boyd, et al.
Published: (2021-12-01)

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
by: Dave Singh, et al.
Published: (2019-08-01)

Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes.
by: Kevin D Schuster, et al.
Published: (2019-01-01)

A Novel Catecholopyrimidine Based Small Molecule PDE4B Inhibitor Suppresses Inflammatory Cytokines in Atopic Mice
by: Baskaran Purushothaman, et al.
Published: (2018-05-01)

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
by: Franziska Elena Herrmann, et al.
Published: (2022-04-01)